A CLINICAL STUDY OF INFLAMMATORY AND METABOLIC DISTURBANCES ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME
Downloads
Objective: This study provides a comparative analysis of metabolic and inflammatory profiles in PCOS patients against approximate normal ranges. Method: Regarding hereditary diseases, thyroid gland issues were the most frequently reported (41.18%), followed by diabetes (35.29%), while a smaller proportion reported no hereditary diseases listed (23.53%). These findings provide insights into the prevalence of certain hereditary metabolic conditions within the studied group of PCOS patients. Results: The data reveals that, on average, PCOS patients exhibit elevated levels of CRP (10.74 ± 1.82 mg/L), total cholesterol (TC: 205.09 ± 4.81 mg/dL), triglycerides (TG: 205.09 ± 15.84 mg/dL), blood sugar (138.45 ± 7.87 mg/dL), and HbA1c (6.39 ± 0.268%), suggesting increased inflammation, dyslipidemia, and impaired glucose metabolism. Furthermore, vitamin D levels are markedly deficient in this group (9.64 ± 0.57 ng/mL). While hemoglobin (Hb) levels are within the lower end of the normal range (11.5 ± 0.315 g/dL), the average BMI of the PCOS patient group falls within the overweight category (29.58 ± 1.68 kg/m²). These findings highlight significant metabolic and inflammatory alterations in PCOS patients compared to established normal ranges. Finally, concludes that PCOS patients exhibit significant metabolic and inflammatory disturbances, including inflammation (elevated CRP), dyslipidemia (elevated TC and TG), impaired glucose metabolism (elevated blood sugar and HbA1c), and vitamin D deficiency. They also have a tendency towards being overweight. Furthermore, there is a notable prevalence of hereditary thyroid issues and diabetes within this group. These factors collectively contribute to an increased risk of cardiovascular disease and type 2 diabetes. We emphasize early detection of PCOS and implementation of strategies to address elevated CRP, cholesterol, triglycerides, blood sugar, and HbA1c through lifestyle modifications (diet, exercise) and potentially pharmacological interventions. Novelty: Polycystic Ovary Syndrome (PCOS) is a serious multi-organ endocrinopathy that affects not only fertility but also the overall metabolic health of the patient. Although studies have shown that the impact of PCOS on life expectancy is negligible, type of live for females with this diseases is significantly decrease due to metabolic complications complex. It is important to recognize this syndrome as early as possible, which reduces the intensity of unpleasant symptoms and prevents long-term metabolic consequences.
R. Azziz, “Introduction: Determinants of polycystic ovary syndrome,” Fertility and Sterility, vol. 106, no. 1, pp. 4–5, 2016, doi: 10.1016/j.fertnstert.2016.05.009.
M. T. Sheehan, “Polycystic ovarian syndrome: Diagnosis and management,” Clinical Medicine & Research, vol. 2, no. 1, pp. 13–27, 2004, doi: 10.3121/cmr.2.1.13.
S. Palomba, S. Santagni, A. Falbo, and G. B. La Sala, “Complications and challenges associated with polycystic ovary syndrome: Current perspectives,” International Journal of Women’s Health, vol. 7, pp. 745–763, 2015, doi: 10.2147/IJWH.S70314.
N. A. G. H. Al-Fatlawi, “Toll-like receptor 4 and cytotoxic T cells CD8+ are prognostic markers in type 1 diabetes mellitus,” Journal of the Pakistan Medical Association, vol. 73, no. 9, pp. S20–S25, 2023, doi: 10.47391/JPMA.IQ-04.
R. L. Rosenfield and D. A. Ehrmann, “The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited,” Endocrine Reviews, vol. 37, no. 5, pp. 467–520, 2016, doi: 10.1210/er.2015-1104.
N. K. Fakher and S. A. Hammood, “Study of some immunological disorders associated with polycystic ovary syndrome,” Egyptian Journal of Medical Microbiology, vol. 34, no. 4, 2025, doi: 10.21608/ejmm.2025.372548.1547.
O. Papalou and E. Diamanti-Kandarakis, “The role of stress in PCOS,” Expert Review of Endocrinology & Metabolism, vol. 12, no. 2, pp. 87–95, 2017, doi: 10.1080/17446651.2017.1292125.
J. A. Marcondes, S. A. Yamashita, G. A. Maciel, E. C. Baracat, and A. Halpern, “Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity,” Gynecological Endocrinology, vol. 23, no. 5, pp. 273–278, 2007, doi: 10.1080/09513590701192529.
N. K. Stepto et al., “Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp,” Human Reproduction, vol. 28, no. 3, pp. 777–784, 2013, doi: 10.1093/humrep/des463.
Q. Liu, Y. J. Xie, L. H. Qu, M. X. Zhang, and Z. C. Mo, “Dyslipidemia involvement in the development of polycystic ovary syndrome,” Taiwanese Journal of Obstetrics and Gynecology, vol. 58, no. 4, pp. 447–453, 2019, doi: 10.1016/j.tjog.2019.05.003.
J. Rojas et al., “Polycystic ovary syndrome, insulin resistance, and obesity: Navigating the pathophysiologic labyrinth,” International Journal of Reproductive Medicine, vol. 2014, p. 719050, 2014, doi: 10.1155/2014/719050.
D. P. Sonne and B. Hemmingsen, “Comment on American Diabetes Association. Standards of medical care in diabetes-2017,” Diabetes Care, vol. 40, no. 6, pp. e92–e93, 2017, doi: 10.2337/dc17-0235.
W. Chen and Y. Pang, “Metabolic syndrome and PCOS: Pathogenesis and the role of metabolites,” Metabolites, vol. 11, no. 12, p. 869, 2021, doi: 10.3390/metabo11120869.
B. Thorand et al., “Elevated levels of interleukin-18 predict the development of type 2 diabetes: Results from the MONICA/KORA Augsburg Study, 1984–2002,” Diabetes, vol. 54, no. 10, pp. 2932–2938, 2005, doi: 10.2337/diabetes.54.10.2932.
B. Aslanipour, M. Alan, and I. Demir, “Decreased levels of liver-expressed antimicrobial peptide-2 and ghrelin are related to insulin resistance in women with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 36, no. 3, pp. 222–225, 2020, doi: 10.1080/09513590.2019.1650338.
D. A. Ehrmann, “Polycystic ovary syndrome,” New England Journal of Medicine, vol. 352, no. 12, pp. 1223–1236, 2005, doi: 10.1056/NEJMra041536.
M. N. Islam et al., “Liver-expressed antimicrobial peptide 2 antagonizes the effect of ghrelin in rodents,” Journal of Endocrinology, vol. 244, no. 1, pp. 13–23, 2020, doi: 10.1530/JOE-19-0341.
Bener and N. Saleh, “Low vitamin D and bone mineral density with depressive symptoms burden in menopausal and postmenopausal women,” Journal of Mid-life Health, vol. 6, no. 3, pp. 108–114, 2015, doi: 10.4103/0976-7800.164756.
Z. Saadia, “Follicle stimulating hormone (LH:FSH) ratio in polycystic ovary syndrome (PCOS)-obese vs. non-obese women,” Medical Archives, vol. 74, no. 4, pp. 289–293, 2020, doi: 10.5455/medarh.2020.74.289-293.
Dawood, N. Alkafrawy, S. Saleh, R. Noreldin, and S. Zewain, “The relationship between IL-18 and atherosclerotic cardiovascular risk in Egyptian lean women with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 34, no. 4, pp. 294–297, 2018, doi: 10.1080/09513590.2017.1395827.
Copyright (c) 2026 Noor Alamer
This work is licensed under a Creative Commons Attribution 4.0 International License.
